




CONGRATULATIONS!



Knights Templar Eye Foundation, Inc.

201 Cross Timbers Rd., Bldg. 4-Suite 300, Flower Mound, TX 75028 Telephone (214) 888-0220, Fax (214) 888-0230



Archana Jalligampala, PhD University of Louisville, School of Medicine Department of Orbithalmology and Visual Sciences 301 E. Muhammad Ali Blvd. Room 415

Louisville, KY 40202

Dear Dr. Jalligampala:

On behalf of the Officers and Trustees of the Knights Templar Eye Foundation, Inc., I am happy to inform you that we have allocated the amount of \$90,000 for your grant proposal: Therapeutic efficacy of a novel stereopure antisense oligonucleotide (ASO) - Wave1, to treat P23H autosomal dominant retinitis pigmentosa.

The first installment of \$80,000 will be mailed as soon as we receive the enclosed form. The balance of \$10,000 will be issued after you have furnished the Knights Templar Eye Foundation a progress report along with a financial report for review by our Scientific Advisory Committee. Please submit these reports to our office as soon as possible after March 1, 2024, either hard copy or electronic (pdf) to manager@ktef.us. Include a status of the research project in addition to a summary of the utilization of funds. There is no specific format, however a progress of your work and an allocation of the funds is required. All unused funds must be returned to the Knights Templar Eye Foundation.

At the end of the grant period we require a final financial report along with a final status

Please note that the award funds MUST be placed in an institutional account and utilized for the items in the budget as approved in the application. Transfer of funds to another institution during the award period must be approved in advance by the Knights Templar Eye

You should also be aware that you are not eligible to accept this grant if you have received notice of approval as principal investigator or co-investigator on a R01, K08, K23, or R21 grant from the National Institutes of Health prior to June 1, 2023, or a business grant (SRIR and STTR) or have served as a PI of a collaborative grant (R24, R15, or U10). You may have been funded previously by a NIH institutional grant, e.g. training grant (T32) or individual postdoctoral fellowship (F32). Enclosed is a statement which must be signed and returned to this office along with instructions indicating the specific payee of the check, address, taxID number, please send this back no later than Friday April 29, 2023.

We extend to you our very best wishes for your success in this vital area of research.

David J. Kussman

Archana Jalligampala, Ph.D., a postdoctoral associate in the UofL Department of Ophthalmology and Visual Sciences, has received \$90,000 for translational research to evaluate the effectiveness of a treatment for retinitis pigmentosa. The one-year funding provided by the Knights Templar Eye Foundation Inc. will support Dr. Jalligampala's work to explore a novel stereopure antisense oligonucleotide as a treatment approach for one of the common forms of autosomal dominant retinitis pigmentosa among North Americans, an inherited condition that leads to night blindness and gradual loss of vision





